CNBC’s Angelica Peebles and Vertex JournavxPharmaceuticals CEO Reshma Kewalramani join 'Squawk on the Street' to discuss the ...
The company announced that the Food and Drug Administration (FDA) has approved Journavx, a twice-daily pill that it described as a "highly selective NaV1.8 pain signal inhibitor for the treatment of ...
The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under ...
Vertex Pharmaceuticals won FDA approval for its non-opioid painkiller Journavx. Vertex stock jumped in late trading.
The U.S. Food and Drug Administration has approved Vertex Pharmaceuticals’ (VRTX) non-opioid painkiller pill that has a low risk of addiction. Vertex is the first drugmaker in decades to gain U.S.
This category includes pain that can pop up due to injuries, following surgeries, or as a symptom of an illness. What makes Journavx different is its unique way of working; instead of acting on the ...
Below, check out the roundup of California Healthline's coverage. For today's national health news, read KFF Health News' Morning Briefing.